Alcon
About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Employees: 25,315
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
43% more call options, than puts
Call options by funds: $236M | Put options by funds: $165M
34% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 65
14% more funds holding in top 10
Funds holding in top 10: 14 [Q2] → 16 (+2) [Q3]
7% more capital invested
Capital invested by funds: $22.7B [Q2] → $24.2B (+$1.51B) [Q3]
4% more funds holding
Funds holding: 621 [Q2] → 643 (+22) [Q3]
2.48% less ownership
Funds ownership: 51.59% [Q2] → 49.11% (-2.48%) [Q3]
19% less repeat investments, than reductions
Existing positions increased: 186 | Existing positions reduced: 230
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham David Saxon 25% 1-year accuracy 15 / 61 met price target | 27%upside $108 | Buy Maintained | 17 Dec 2024 |
Keybanc Brett Fishbin 65% 1-year accuracy 13 / 20 met price target | 26%upside $107 | Overweight Maintained | 15 Oct 2024 |
BTIG Ryan Zimmerman 63% 1-year accuracy 30 / 48 met price target | 25%upside $106 | Buy Maintained | 14 Oct 2024 |
Financial journalist opinion
